Semaglutide

Semaglutide is a revolutionary CLP-1 receptor agonist that was originally developed for patients with Type 2 diabetes, but when providers and pharmaceutical developers noticed how much weight heir patients were losing, they began to study semaglutide exclusively for weight loss. A series of clinical trials knowns as the STEP clinical trials demonstrated that almost 90% of patients lost 5% or more of their body weight. There is no other weight loss drug on the market that compares. In Junes of 2022, the FDA approved semaglutide for weight loss.

Semaglutide acts like GLP-1 (a gut hormone) to:

• Decrease blood sugar
• Decrease glucagon synthesis
• Help you feel fuller longer
• Suppress hunger signals

Commonly reported GI side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, site reactions, fatigue, and headaches.

The amount of weight that can be lost with semaglutide varies from case to case based on the patient’s metabolism, health and dietary habits, and other factors. Generally, patients have lost anywhere from 10% to 20% if their body weight with the help of this treatment option.

Those with a history of thyroid cancer or hypoglycemia and those clinically underweight should not use semaglutide.

Health history, medications, and body weight information will be carefully reviewed by a licensed provider to determine each candidate’s eligibility.